{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:48:09Z","timestamp":1761518889059,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.3816\/cbc.2007.s.007","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T21:04:37Z","timestamp":1221167077000},"page":"S6-S10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S1","title":["Dose-Dense Therapy in the Treatment of Early-Stage Breast Cancer: An Overview of the Data"],"prefix":"10.3816","volume":"8","author":[{"given":"Heather L.","family":"McArthur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford A.","family":"Hudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"American Cancer Society","key":"10.3816\/CBC.2007.s.007_bib1"},{"key":"10.3816\/CBC.2007.s.007_bib2","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","article-title":"Effect of screening and adjuvant therapy on mortality from breast cancer","volume":"353","author":"Berry","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2007.s.007_bib3","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1200\/JCO.2005.03.6053","article-title":"Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort","volume":"24","author":"Elkin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.007_bib4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/264542a0","article-title":"Predicting the course of Gompertzian growth","volume":"264","author":"Norton","year":"1976","journal-title":"Nature"},{"key":"10.3816\/CBC.2007.s.007_bib5","first-page":"7067","article-title":"A Gompertzian model of human breast cancer growth","volume":"48","author":"Norton","year":"1988","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2007.s.007_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.1995.03520310040027","article-title":"Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results","volume":"273","author":"Bonadonna","year":"1995","journal-title":"JAMA"},{"key":"10.3816\/CBC.2007.s.007_bib7","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.007_bib8","unstructured":"Hudis C. Dose-dense adjuvant chemotherapy for breast cancer. In: American Society of Clinical Oncology; 2005; Orlando, FL; 2005."},{"issue":"suppl 1","key":"10.3816\/CBC.2007.s.007_bib9","first-page":"S9","article-title":"Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO \u2013 M1G1 study","volume":"82","author":"Venturini","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2007.s.007_bib10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/jnci\/dji398","article-title":"Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial","volume":"97","author":"Venturini","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2007.s.007_bib11","doi-asserted-by":"crossref","unstructured":"M\u00f6bus V, Untch M, Bois AD, et al. Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (\u22654 +LN). First results of an AGO-trial. Presented at: the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, LA. Abstract 513.","DOI":"10.1200\/jco.2004.22.90140.513"},{"issue":"suppl 1","key":"10.3816\/CBC.2007.s.007_bib12","first-page":"S20","article-title":"Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional schedule chemotherapy in high-risk breast cancer patients (\u22654 +LN). Mature results of an AGOtrial","volume":"100","author":"Moebus","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2007.s.007_bib13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2003.05.135","volume":"21","author":"Therasse","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.007_bib14","unstructured":"Burnell M, Levine M, Chapman JA, et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX."},{"key":"10.3816\/CBC.2007.s.007_bib15","unstructured":"Sparano J, Wang M, Martino S, et al. Phase III study of doxorubicincyclophosphamide followed by paclitaxel or docetaxel given every three weeks or weekly in patients with axillary node-positive or highrisk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Presented at: 28th San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, TX. Abstract 48."},{"issue":"18 suppl","key":"10.3816\/CBC.2007.s.007_bib16","first-page":"6s","article-title":"Phase III study of doxorubicincyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup Trial E1199","volume":"25","author":"Sparano","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.s.007_bib17","first-page":"S115","article-title":"Phase II randomized adjuvant trial of dose-dense docetaxel (DOC) before or after doxorubicin\/cyclophosphamide (AC) in axillary node-positive breast cancer","volume":"100","author":"Puhalla","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"18 suppl","key":"10.3816\/CBC.2007.s.007_bib18","first-page":"12s","volume":"24","author":"Ellis","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CBC.2007.s.007_bib19","first-page":"S114","article-title":"Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2\/neu overexpressed\/amplified breast cancer (BCA)","volume":"100","author":"Dang","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"10.3816\/CBC.2007.s.007_bib20","first-page":"S284","article-title":"A pilot study of growth factor (GF) omission during paclitaxel (T) for women with early breast carcinoma (BC)","volume":"100","author":"Sugarman","year":"2006","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911708035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911708035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:11:02Z","timestamp":1761513062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911708035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":20,"alternative-id":["S1526820911708035"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2007.s.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-Dense Therapy in the Treatment of Early-Stage Breast Cancer: An Overview of the Data","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2007.s.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}